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Abstract
Background: Diabetes has been great problem worldwide.
Continuous Glucose Monitoring (CGM) has been in focus,
and useful CGM, FreeStyle Libre (Abbott) has been
introduced to clinical ordinary practice of medicine.
Case and results: The patient was 57 year-old female with
type 1 diabetes mellitus (T1DM), who showed BMI 20.6
kg/m2, HbA1c 8.6%. She was on CGM measured glucose
every 15 minutes in 24 hours for 14 days. Treatment
included 3 times of Insulin Aspart and once of Insulin
Glargin. She showed characteristic pattern of blood
glucose profile according to the working schedule of the
day.
Discussion and conclusion: The beneficial points of
FreeStyle Libre have been convenient and accurate for
clinical use for reducing hypoglycemia episodes.
Treatment using CGM associated with multiple daily
insulin injection (MDI) confers similar or greater benefits
for glycemic profile. When evening insulin was not
injected one day, blood glucose increased 320 mg/dL,
suggesting 64 g of carbohydrate ingested for supposed
calculation. These results suggest that CGM could
recommend the timing and doses of insulin injection
according to the lifestyle of the patients with clinical
merit.
Keywords: Continuous glucose monitoring; FreeStyle
libre; Type 1 diabetes mellitus; Type 2 diabetes mellitus;
Blood glucose profile
List of abbreviations: DCCT: Diabetes Control and
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Introduction
The prevalence of diabetes has been increasing globally and
a multifactorial approach is necessary to decrease several risk
of complications in this situation [1]. Maintaining the adequate
blood glucose has been the key to prevent microvascular and
macrovascular diseases [2]. Consequently, optimizing glucose
levels has been required for the patients with Type 1 Diabetes
Mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) [3].
There have been treatment of insulin therapy for older
adults with T1DM and T2DM, and it has performed
successfully with the development of continuous glucose
monitoring (CGM).
Patients with T1DM has been living longer [4], and its
number of older adults has been growing [5]. Consequently,
insulin-treated older T1DM patients have longer diabetic
history and tend to have micro- and macrovascular
complications and other comorbidities [5,6].
Such patients have higher risk for severe hypoglycemia,
leading to other severe states such as cerebral vascular
accident (CVA), myocardial infarcts, arrhythmias, temporary or
permanent cognitive impairment and death [5,7].
In order to avoid hypoglycemia, The American Diabetes
Association (ADA) has recommended higher HbA1c and
glycemic goals which vary according to each comorbid status in
older adults [6]. CGM has been effective for avoid
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hypoglycemia and the The DIAMOND study with T1DM treated
with multiple injection therapy, showed improved HbA1c with
less hypoglycemia [8]. This study was a prospective,
randomized clinical trial of CGM for adults.
There has been a useful device for CGM, which has been
introduced to clinical practice. It is FreeStyle Libre, produced
by Abbott, USA [9,10]. In this study, daily profile of blood
glucose in patient with T1DM was measured by FreeStyle Libre
and investigated detail glucose fluctuation.
Case Presentation
The patient was 57 year-old female with T1DM. She was
diagnosed as T1DM 10 years ago, and has been continued
insulin therapy after that. Her recent HbA1c has been around
7.5%-8.6% and blood glucose ranges from 50 mg/dL to 400
mg/dL. These results are supposed to be rather unstable and
not in satisfactory diabetic controlled state.
Consequently, we tried to evaluate her current diabetic
condition in detail, and we have measured the profile of blood
glucose using FreeStyle Libre (Abbott).
On physical examination, her consciousness and vitals are
normal, and heart, lung, abdomen and neurological findings
were unremarkable. She showed 159 cm in height, 52 kg in
weight, BMI 20.6 kg/m2, abdominal circumference 83 cm and
thigh circumference 42 cm.
Laboratory findings on January 2018 were as follows:
postprandial blood glucose on 216 mg/dL after 150 min of
meal, and HbA1c was 8.5%. She showed unremarkable data
about complete blood count, liver function test, renal function
and lipids profile.
Current insulin treatment included Novo rapid (Novo
Nordisk) 3 times a day, and Insulin Glargine (Eli Lilly and
Company) of once a day. The former is Insulin Aspart given by
pre–filled pen including 100 units/mL, and the latter is Insulin
Glargine by BS injection kit FFP including 300 units/mL. The
time and units are as follows: the former is injected 8, 10, 10
units on 0700h, 1230h, 1830h and the latter is injected 11
units on 2300h.
Continuous glucose monitoring
CGM was studied for 14 days. Using CGM device, blood
profile were measured every 15 minutes in 24 hours. We used
sensor-based device for blood glucose monitoring, which is the
FreeStyle Libre Flash Glucose Monitoring system, produced by
Abbott Diabetes Care Inc, Alameda, CA, USA. This is firstly
commercial-based available sensor systems associated with
several beneficial points [11,12].
It has some advantages for replacing blood glucose testing
and detecting trends and tracking patterns in order to detect
the episodes of hyperglycemia and hypoglycemia.
Characteristic strong points are accurate, convenient and small
size for practical use [10,13]. The sensor is put and wearable
on the back of the upper arm during 14 days and can
automatically preserve swinging glucose data every 15 min for
14 days [9,10,14,15].
Results of CGM
The mean value of the glycemic profile over 14 days is
shown in Figure 1. In general, blood glucose tends to rise at
0800-1000 h after breakfast intake. During working, she keeps
on walking all the time, then blood glucose level usually falls
around 1100-1230 h. After taking light lunch, she moves again
well in the second half of the afternoon, leading to blood
glucose decrease in the evening. At night, she always relaxes at
home, and does not move much after dinner.
Figure 1 Average blood glucose for 14 days by continuous
glucose monitoring (CGM).
The glucose profiles in three different characteristic
situations were shown in Figure 2. The lifestyle on January
28th was usual and she was working from morning until
evening (Figure 2a). After taking breakfast, blood glucose
increases, decreases before lunch and keeps low during
1200-1230 h. Glucose level was stable in the afternoon, and
became low during 1700-1800 h because of continuation of
walking. At night, glucose value was stable due to relaxed time
at home.
Figure 2 Blood glucose profile in 3 days by continuous
glucose monitoring (CGM). Subject worked 0900h-1800h
with regular insulin treatment (2a). Subject did not work all
day with regular insulin treatment (2b). Subject worked
1500-2100 h without insulin injection at 1900 h (2c).
Endocrinology Research and Metabolism
Vol.2 No.1:10
2018
2 This article is available from: http://www.imedpub.com/endocrinology-research-and-metabolism/
She was off on January 30th without work, and did not walk
around for the day (Figure 2b). Therefore, results with less
fluctuation in blood glucose were obtained. The increase in
blood glucose after 1530 h was due to intake of sugar-rich
cake.
She worked during 1500-2100 h on Feb.1st (Figure 2c).
Glucose fluctuation during 0900-1230h are compared with
Figures 2a and 2c. When moving frequently in the morning,
blood sugar falls well (Figure 2a), but when keeping still, it
does not go down (Figure 2c). As she started working from
1500 h, blood sugar gradually declined. She took snacks in
1830 h, but she could not inject the insulin on the evening.
After that, hyperglycemia persisted for long, although Glargine
was given on 2300 h. The hyperglycemia lasted until the next
morning, in which blood glucose was 220 mg/dL at 0700 h.
Discussion
Treatment using real-time CGM (rtCGM) associated with
multiple daily insulin (MDI) injection confers similar or greater
benefits for glycemic profile [16]. Moreover, there have been
lots of studies that use of rtCGM could improve glycemic
control in children and adults with T1DM [17-20]. The
beneficial points of rtCGM are found in cases who wear CGM
devices more frequently and respond to regulate appropriately
according to the glucose data provided [17,21].
Especially, CGM is clinically important for cases with T1DM
on MDI injection [22]. CGM has the potential benefits of
effective use of glycemic rate of change (ROC) arrows for dose
adjustments of insulin [23].
As to the insulin treatment, pre-meal glycemic slope
predicts post-meal glycemic excursions and may help inform
insulin dosing decisions. Rate-of-change arrows on existing
devices obscure clinically actionable glycemic trend
information from CGM users [24].
CGM devices have developed over the past years for the
standard care for patients with T1DM [25]. Compared with the
traditional blood glucose monitoring (BGM), recent CGM data
represent 24-hour glycemic variability and prediction of
glucose changes simultaneously. Recently, there has been
broader application for patients with various states [26].
Furthermore, Food and Drug Administration (FDA) in United
States approved the management decisions in 2016 that
include insulin dosing from CGM values [27].
CGM devices record interstitial glucose level and have the
advantage of providing detail and precise glucose readings,
with recently a new generation of implantable variability
[28,29]. Furthermore, CGM has shown improvement in
glucose variability, measured as HbA1c, reduction of
hypoglycemia and cost-effectiveness [30].
Recently, clinical practice guidelines have been generally
simplified the criteria for CGM use by the endocrine society
[31]. According to the data from 11 RCTs using CGM for T1DM,
CGM would alters HbA1c (95% CI) by -0.28% (-0.47, -0.09), and
reduces the risk of hypoglycemia, particularly with lower
HbA1c levels [31].
As for T1DM case studied in this study, there seemed to be
three characteristic findings. Firstly, blood glucose increased
during 0800-1000 h, which is probably due to rather excess
intake of carbohydrate or shortage of rapid effective insulin.
Secondly, blood glucose was decreasing due to the effect of
continuous physical movement. It is from her lifestyle and
habit that she always moves and walks around without sitting
during working.
Thirdly, when insulin injection was not done at 1900h,
hyperglycemia has lasted overnight. In this point, blood
glucose increased from 76 to 396 mg/dL, ie., rise of 320
mg/dL. In T1DM, there is averagely an increase of 5 mg/dL of
blood glucose per 1g of carbohydrate intake. Then the ingested
sugar amount was calculated to be about 64 g. Ingested
carbohydrate was actually 72 g, which seemed to be roughly
consistent.
Conclusion
As to this investigation, blood glucose profile can be clarified
in detail by application of CGM, indicating clinical usefulness.
Furthermore, it is possible to recommend the timing and dose
of insulin injection according to the lifestyle of the patient,
suggesting a great clinical merit. These results would be useful
as basic data for better treatment and clinical research in
T1DM.
Supplement
This study was conducted in compliance with the ethical
principles of the Declaration of Helsinki. In addition, it was
with Japan’s Act on the Protection of Personal Information
along with the Ministerial Ordinance on Good Clinical Practice
(GCP) for Drug (Ordinance of Ministry of Health and Welfare
No. 28 of March 27, 1997). We held ethical committee
meeting including physicians, nurse, pharmacist, clinical
engineer and academic experts. Informed consent was
obtained from the subject.
The authors would like to thank the patient and staffs for
their cooperation and support. The authors declare that they
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